RECRUITINGPhase 4

Molecular Signatures of Cutaneous Dupilumab Response

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Sponsor

University of California, San Francisco

Enrollment

15 participants

Sites

1 locations

Start Date

February 2023

Completion

February 2026

Atopic DermatitisDupilumab

Enrollment & Timeline

Recruiting

Target enrollment (estimated)

Target N

participants

Sites

locations

Duration

3.0 years

total trial span

Feb 2023Month 38 of 36Feb 2026

100% of trial timeline elapsed

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks

baseline and 8-12 weeks

Change in EASI score from baseline to 8-12 weeks. Scores range from 0 to 72, with higher scores indicating more severity.

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

No linked publications found in PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Fetching protocol from ClinicalTrials.gov…

RECRUITINGPhase 4

Molecular Signatures of Cutaneous Dupilumab Response

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Sponsor

University of California, San Francisco

Enrollment

15 participants

Sites

1 locations

Start Date

February 2023

Completion

February 2026

Atopic DermatitisDupilumab

Enrollment & Timeline

Recruiting

Target enrollment (estimated)

Target N

participants

Sites

locations

Duration

3.0 years

total trial span

Feb 2023Month 38 of 36Feb 2026

100% of trial timeline elapsed

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks

baseline and 8-12 weeks

Change in EASI score from baseline to 8-12 weeks. Scores range from 0 to 72, with higher scores indicating more severity.

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

No linked publications found in PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Eligibility

Min Age

18 Years

Sex

all

Healthy Volunteers

View full criteria

Inclusion Criteria:

1. 18 years of age or older
2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7

Exclusion Criteria:

1. Known pregnancy
2. Known immunodeficiencies
3. Known parasitic infection -

Molecular Signatures of Cutaneous Dupilumab Response

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Molecular Signatures of Cutaneous Dupilumab Response

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Eligibility

Trial Sites (1)